Effect of Vistusertib alone of in combination with fulvestrant in human breast cancer PDX models of acquired endocrine resistance
收藏NIAID Data Ecosystem2026-04-25 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP221321
下载链接
链接失效反馈官方服务：
资源简介：
Combined therapy of vistusertib with fulvestrant showed synergy in estrogen receptor positive PDX models of resistance to endocrine therapy and delayed tumour progression after cessation of therapy. To understand the transcriptional impact of vistusertib alone or in combination with fulvestrant in tumours modelling acquisition of endocrine therapy.
创建时间：
2020-10-07
